Immunohistochemical localization of the cloned μ opioid receptor in the rat CNS

doi:10.1016/0891-0618(95)00055-C

Journal of Chemical Neuroanatomy

Volume 8, Issue 4, May 1995, Pages 283-305

https://doi.org/10.1016/0891-0618(95)00055-C Get rights and content

Abstract

Three opioid receptor types have recently been cloned that correspond to the pharmacologically defined μ, δ and κ₁ receptors. In situ hybridization studies suggest that the opioid receptor mRNAs that encode these receptors have distinct distributions in the central nervous system that correlate well with their known functions. In the present study polyclonal antibodies were generated to the C terminal 63 amino acids of the cloned μ receptor (335–398) to examine the distribution of the μ receptor-like protein with immunohistochemical techniques. μ receptor-like immunoreactivity is widely distributed in the rat central nervous system with immunoreactive fibers and/or perikarya in such regions as the neocortex, the striatal patches and subcallosal streak, nucleus accumbens, lateral and medial septum, endopiriform nucleus, globus pallidus and ventral pallidum, amygdala, hippocampus, presubiculum, thalamic and hypothalamic nuclei, superior and inferior colliculi, central grey, substantia nigra, ventral tegmental area, interpeduncular nucleus, medial terminal nucleus of the accessory optic tract, raphe nuclei, nucleus of the solitary tract, spinal trigeminal nucleus, dorsal motor nucleus of vagus, the spinal cord and dorsal root ganglia. In addition, two major neuronal pathways, the fasciculus retroflexus and the stria terminalis, exhibit densely stained axonal fibers. While this distribution is in excellent agreement with the known μ receptor binding localization, a few regions, such as neocortex and cingulate cortex, basolateral amygdala, medial geniculate nucleus and the medial preoptic area fail to show a good correspondence. Several explanations are provided to interpret these results, and the anatomical and functional implications of these findings are discussed.

References (75)

S.F. Atweh et al.
Autoradiogaphic localization of opiate receptors in rat brain. I. Spinal cord and lower medulla
Brain Res.
(1977)
S.F. Atweh et al.
Autoadiogaphic localization of opiate receptors in rat brain. II. The brain stem
Brain Res.
(1977)
S.F. Atweh et al.
Autoradiogaphic localization of opiate receptors in rat brain. III. The telencephalon
Brain Res.
(1977)
K. Befort et al.
Chromosomal localization of the δ opioid receptor gene to human lp34.3-p36.1 and mouse 4D bands by in situ hybridization
Genomics
(1994)
H.W. Berendse et al.
Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat
Neuroscience
(1991)
D. Besse et al.
Pre- and postsynaptic distribution of μ, δ and κ opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord
Brain Res.
(1990)
C.J.C. Boersma et al.
Technical aspects of opioid receptor localization: Detection of opioid receptor proteins by immunocytochemistry or with a biotinylated dynorphin analog
J. Neurosci. Methods
(1994)
C.J. Coscia et al.
A monoclonal antiidiotypic antibody to μ and δ opioid receptors
Mol. Brain Res.
(1991)
R.P. Dilts et al.
Autoradiographic localization of μ-opioid and neurotensin receptors within the mesolimbic dopamine system
Brain Res.
(1989)
J.A. Glasel et al.
Rabbit anti-idiotypic antibodies raised against monoclonal anti-morphine IgG block μ and δ opiate receptor sites
Life Sci.
(1985)

K. Guan et al.

Eukaryotic proteins expressed in Escherichia coli: An improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase

Anal. Biochem.

(1991)

A.H.S. Hassan et al.

Immunocytochemical demonstration of opioid receptors in selected rat brain areas and neuroblastoma X glioma hybrid (NG108-15) cells using a monoclonal anti-idiotypic antibody

Neuroscience

(1989)

M. Herkenham et al.

Cell clusters in the nucleus accumbens of the rat, and the mosaic relationship of opiate receptors, acetylcholinesterase and subcortical afferent termination

Neuroscience

(1984)

S. Iyengar et al.

μ-, δ-, and ϵ opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: Subchronic tolerance studies of endogenous opioid peptides

Brain Res.

(1987)

H. Khachaturian et al.

Dynorphin immunocytochemistry in the rat central nervous system

Peptides

(1982)

C.A. Kozak et al.

Murine chromosomal location of the μ and κ opioid receptor genes

Genomics

(1994)

C. Lamotte et al.

Opiate receptor binding in primate spinal cord: Distribution and changes after dorsal root section

Brain Res.

(1976)

R. Maneckjee et al.

Characterization of a polyclonal antibody to the μ opioid receptor

J. Neuroimmunol.

(1988)

A. Mansour et al.

Opioid receptor mRNA expression in the rat CNS: Anatomical and functional implications

Trends Neurosci.

(1995)

A. Mansour et al.

Immunohistochemical localization of the κ₁opioid receptors

Regulatory Peptides

(1994)

A. Mansour et al.

κ₁ receptor mRNA distribution in the rat CNS: Comparison to κ receptor binding and prodynorphin mRNA

Mol. Cell. Neurosci.

(1994)

A. Mansour et al.

Mu opioid receptor mRNA expression in the rat CNS: Comparison to mu receptor binding

Brain Res.

(1994)

A. Mansour et al.

Anatomy of CNS opioid receptors

Trends Neurosci.

(1988)

A. Mansour et al.

Delta opioid receptor mRNA distribution in the brain: Comparison to delta receptor binding and proenkephalin mRNA

J. Chem. Neuroanatomy

(1993)

G.W. Pasternak

Multiple μ opiate receptors: Biochemical and pharmacological evidence for multiplicity

Biochem. Pharmacol.

(1986)

D.G. Pfeiffer et al.

Predominant involvement of mu rather than delta or kappa opiate receptors in LH secretion

Peptides

(1983)

J.P. Rosenfeld

Interacting brain stem components of opiateactivated, descending, pain-inhibitory systems

Neurosci. Biobehav. Rev.

(1994)

N.A. Sharif et al.

Discrete mapping of brain mu and delta opioid receptors using selective peptides: Quantitative autoradiography, species differences and comparison with kappa receptors

Peptides

(1989)

D.B. Smith et al.

Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase

Gene

(1988)

R.C. Thompson et al.

Cloning and pharmacological characterization of a rat μ opioid receptor

Neuron

(1993)

J.B. Wiesner et al.

Site of action of β-endorphin-induced changes in lutenizing hormone and prolactin in the ovariectomized rat

Life Sci.

(1984)

P.L. Wood

Multiple opiate receptors: Support for unique mu, delta and kappa sites

Neuropharmacology

(1982)

T.L. Yaksh et al.

Narcotic analgetics: CNS sites and mechanisms of action as revealed by intracerebral injection techniques

Pain

(1978)

T.L. Yaksh et al.

Microinjection of morphine into the periaqueductal grey evokes the release of serotonin from spinal cord

Brain Res.

(1979)

K. Yasuda et al.

Localization of the kappa opioid receptor gene to human chromosome band 8811.2

Genomics

(1994)

A. Zimprich et al.

Cloning and expression of an isoform of the rmu opioid receptor (rmuOR1B)

Regulatory Peptides

(1994)

U. Arvidsson et al.

δ-opioid receptor immunoreactivity: Distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin

J. Neurosci.

(1995)

Cited by (334)

Cell-type specific molecular architecture for mu opioid receptor function in pain and addiction circuits
2023, Neuropharmacology
Opioids are potent analgesics broadly used for pain management; however, they can produce dangerous side effects including addiction and respiratory depression. These harmful effects have led to an epidemic of opioid abuse and overdose deaths, creating an urgent need for the development of both safer pain medications and treatments for opioid use disorders. Both the analgesic and addictive properties of opioids are mediated by the mu opioid receptor (MOR), making resolution of the cell types and neural circuits responsible for each of the effects of opioids a critical research goal. Single-cell RNA sequencing (scRNA-seq) technology is enabling the identification of MOR-expressing cell types throughout the nervous system, creating new opportunities for mapping distinct opioid effects onto newly discovered cell types. Here, we describe molecularly defined MOR-expressing neuronal cell types throughout the peripheral and central nervous systems and their potential contributions to opioid analgesia and addiction.
This article is part of the Special Issue on “Opioid-induced changes in addiction and pain circuits”.
Chronic Morphine Modulates PDGFR-β and PDGF-B Expression and Distribution in Dorsal Root Ganglia and Spinal Cord in Male Rats
2023, Neuroscience
The analgesic effect of opioids decreases over time due to the development of analgesic tolerance. We have shown that inhibition of the platelet-derived growth factor beta (PDGFR-β) signaling eliminates morphine analgesic tolerance in rats. Although the PDGFR-β and its ligand, the platelet-derived growth factor type B (PDGF-B), are expressed in the substantia gelatinosa of the spinal cord (SG) and in the dorsal root ganglia (DRG), their precise distribution within different cell types of these structures is unknown. Additionally, the impact of a tolerance-mediating chronic morphine treatment, on the expression and distribution of PDGF-B and PDGFR-β has not yet been studied. Using immunohistochemistry (IHC), we found that in the spinal cord, PDGFR-β and PDGF-B were expressed in neurons and oligodendrocytes and co-localized with the mu-opioid receptor (MOPr) in opioid naïve rats. PDGF-B was also found in microglia and astrocytes. Both PDGFR-β and PDGF-B were detected in DRG neurons but not in spinal primary afferent terminals. Chronic morphine exposure did not change the cellular distribution of PDGFR-β or PDGF-B. However, PDGFR-β expression was downregulated in the SG and upregulated in the DRG. Consistent with our previous finding that morphine caused tolerance by inducing PDGF-B release, PDGF-B was upregulated in the spinal cord. We also found that chronic morphine exposure caused a spinal proliferation of oligodendrocytes. The changes in PDGFR-β and PDGF-B expression induced by chronic morphine treatment suggest potential mechanistic substrates underlying opioid tolerance.
The opioid system in depression
2022, Neuroscience and Biobehavioral Reviews
Opioid receptors are widely distributed throughout the brain and play an essential role in modulating aspects of human mood, reward, and well-being. Accumulating evidence indicates the endogenous opioid system is dysregulated in depression and that pharmacological modulators of mu, delta, and kappa opioid receptors hold potential for the treatment of depression. Here we review animal and clinical data, highlighting evidence to support: dysregulation of the opioid system in depression, evidence for opioidergic modulation of behavioural processes and brain regions associated with depression, and evidence for opioidergic modulation in antidepressant responses. We evaluate clinical trials that have examined the safety and efficacy of opioidergic agents in depression and consider how the opioid system may be involved in the effects of other treatments, including ketamine, that are currently understood to exert antidepressant effects through non-opioidergic actions. Finally, we explore key neurochemical and molecular mechanisms underlying the potential therapeutic effects of opioid system engagement, that together provides a rationale for further investigation into this relevant target in the treatment of depression.
Spinal γ-Aminobutyric Acid Interneuron Plasticity Is Involved in the Reduced Analgesic Effects of Morphine on Neuropathic Pain
2022, Journal of Pain
Systemic administration of morphine increases serotonin (5-HT) in the spinal dorsal horn (SDH), which attenuates the analgesic effects of morphine on neuropathic pain through spinal 5-HT3 receptors. We hypothesized that dysfunction of the descending serotonergic system, including the periaqueductal gray (PAG), contributes to attenuate the efficacy of morphine on neuropathic pain through spinal 5-HT3 receptors and GABA neurons. Morphine (100 ng) injected into the PAG produced analgesic effects in normal rats, but not in spinal nerve ligation (SNL) rats. In vivo microdialysis showed that PAG morphine increased the SDH 5-HT concentration in both groups. Intrathecal injection of the 5-HT3 receptor antagonist ondansetron and the GABA_A receptor antagonist bicuculline attenuated the analgesic effects of PAG morphine in normal rats, but increased the effects in SNL rats. The increased analgesic effect of PAG morphine induced by bicuculline was reversed by pretreatment with the tropomyosin receptor kinase B (TrkB) antagonist K252a. Activation of spinal 5-HT3 receptors by 2-methyl-5-HT increased the GABA concentration in both groups. Morphine activates GABAergic interneurons in the SDH by activating descending serotonergic neurons. Functional changes in GABA_A receptors from inhibitory to facilitatory through the activation of TrkB receptors may contribute to the attenuated efficacy of morphine against neuropathic pain.
Although morphine provides strong analgesia against acute pain, it has limited efficacy against neuropathic pain. This article demonstrates that functional changes in GABA_A receptors in the spinal dorsal horn after nerve injury might strongly contribute to the attenuation of opioid-induced analgesia for neuropathic pain.
Striatal circuits
2022, Neurocircuitry of Addiction
The striatum is a subcortical structure that serves as the primary input nucleus of the basal ganglia. Through its diverse arrangement of afferent and efferent connections, the striatum regulates the expression of actions by integrating motor commands with cognitive, motivational, and emotional input (Haber, 2016). By merging internal value with external cues, the striatum learns which actions, and in which context, result in the acquisition of a reward and reinforces those actions to guide future reward-driven behavior. If the reward being sought is a drug of abuse, the striatum pathologically promotes actions that lead to acquisition of the substance. Consider the process of drinking a few beers after a stressful week of work. Execution of this behavior requires the selection of a motor plan motivated by an internal drive (e.g., to reduce stress) and the integration of the reward history of that motor action (e.g., drinking previously was rewarding). Once this motor program is learned, through repeated execution and reinforcement, this behavior becomes engrained in striatal circuits and can be elicited almost automatically by sensory cues in the environment—even in the face of known negative consequences (e.g., drinking previously led to poor work performance). As such, the striatum plays a fundamental role in the decisions and actions we make every day, and by extension how we define ourselves through those actions.
Tianeptine induces expression of dual specificity phosphatases and evokes rebound emergence of cortical slow wave electrophysiological activity
2021, Neuroscience Letters
The precise mechanism governing the antidepressant effects of tianeptine is unknown. Modulation of brain glutamatergic neurotransmission has been however implicated, suggesting potential shared features with rapid-acting antidepressants targeting N-methyl-D-aspartate receptors (NMDAR). Our recent studies suggest that a single subanesthetic dose of NMDAR antagonists ketamine or nitrous oxide (N₂O) gradually evoke 1–4 Hz electrophysiological activity (delta-rhythm) of cerebral cortex that is accompanied by molecular signaling associated with synaptic plasticity (e.g. activation of tropomyosin receptor kinase B (TrkB) and inhibition of glycogen synthase kinase 3β (GSK3β)).
We have here investigated the time-dependent effects of tianeptine (30 mg/kg, i.p.) on electrocorticogram, focusing on potential biphasic regulation of the delta-rhythm. Selected molecular markers associated with ketamine's antidepressant effects were analyzed in the medial prefrontal cortex after the treatment using quantitative polymerase chain reaction and western blotting.
An acute tianeptine treatment induced changes of electrocorticogram typical for active wakefulness that lasted for 2–2.5 h, which was followed by high amplitude delta-activity rebound. The levels of Arc and Homer1a, but not c-Fos, BdnfIV and Zif268, were increased by tianeptine. Phosphorylation of mitogen-activated protein kinase (MAPK), TrkB and GSK3β remained unaltered at 2-hours and at 3-hours post-treatment. Notably, tianeptine also increased the level of mRNA of several dual specificity phosphatases (Duspss) – negative regulators of MAPK.
Tianeptine produces acute changes of electrocorticogram resembling rapid-acting antidepressants ketamine and N₂O. Concomitant regulation of Dusps may hamper the effects of tianeptine on MAPK pathway and influence the magnitude of homeostatic emergence of delta-activity and TrkB-GSK3β signaling.

View all citing articles on Scopus

View full text

Immunohistochemical localization of the cloned μ opioid receptor in the rat CNS

Abstract

Brain Res.

Brain Res.

Brain Res.

Genomics

Neuroscience

Brain Res.

J. Neurosci. Methods

Mol. Brain Res.

Brain Res.

Life Sci.

Anal. Biochem.

Neuroscience

Neuroscience

Brain Res.

Peptides

Genomics

Brain Res.

J. Neuroimmunol.

Trends Neurosci.

Regulatory Peptides

Mol. Cell. Neurosci.

Brain Res.

Trends Neurosci.

J. Chem. Neuroanatomy

Biochem. Pharmacol.

Peptides

Neurosci. Biobehav. Rev.

Peptides

Gene

Neuron

Life Sci.

Neuropharmacology

Pain

Brain Res.

Genomics

Regulatory Peptides

δ-opioid receptor immunoreactivity: Distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin

J. Neurosci.